PPARD and hepatocellular carcinoma: On the other hand, Kim et al. reported metabolic reprogramming in sorafenib-resistant HCC identifying PPARβ/δ as a key regulator of glutamine metabolism and reductive carboxylation, consequently inhibition of PPARβ/δ activity reversed metabolic reprogramming in HCC cells and sensitized them to sorafenib, suggesting PPARβ/δ as a potential therapeutic target [106].